Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin-Prevention in Labor Use Study (A-PLUS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women in labor ≥28 weeks Gestational Age (GA) (by best estimate) with a pregnancy with one or more live fetuses who plan to deliver vaginally in a facility.~* Admitted to health facility with clear plan for spontaneous or induced delivery.~* Live fetus must be confirmed via a fetal heart rate by Doptone prior to randomization.~* ≥18 years of age or minors 14-17 years of age in countries where married or pregnant minors (or their authorized representatives) are legally permitted to give consent.~* Have provided written informed consent.~* Pregnant women in labor ≥28 weeks GA (by best estimate) with a pregnancy with one or more live fetuses who plan to deliver vaginally in a facility.~* Admitted to health facility with clear plan for spontaneous or induced delivery.~* Live fetus must be confirmed via presence of a fetal heart rate prior to randomization.~* ≥18 years of age or minors 14-17 years of age in countries where married or pregnant minors (or their authorized representatives) are legally permitted to give consent.~* Have provided written informed consent \[Note: written informed consent may be obtained during antenatal care, but verbal re-confirmation may be needed (per local regulations) at the time of randomization\].~Exclusion Criteria:~* Non-emancipated minors (as per local regulations)~* Evidence of chorioamnionitis or other infection requiring antibiotic therapy at time of eligibility (however, women given single prophylactic antibiotics with no plans to continue after delivery should not be excluded).~* Arrhythmia or known history of cardiomyopathy.~* Allergy to azithromycin or other macrolides that is self-reported or documented in the medical record.~* Any use of azithromycin, erythromycin, or other macrolide in the 3 days or less prior to randomization.~* Plan for cesarean delivery prior to randomization.~* Preterm labor undergoing management with no immediate plan to proceed to delivery.~* Advanced stage of labor (\>6 cm or 10 cm cervical dilation per local standards) and pushing or too distressed to understand, confirm, or give informed consent regardless of cervical dilation.~* Are not capable of giving consent due to other health problems such as obstetric emergencies (for example, antepartum hemorrhage) or mental disorder.~* Any other medical conditions that may be considered a contraindication per the judgment of the site investigator.~* Previous randomization in the trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: EXPERIMENTAL): The study intervention is a single 2 g dose of directly observed oral azithromycin.
- Placebo (Type: PLACEBO_COMPARATOR): By random allocation, participants will receive four oral placebo pills containing a non-antimicrobial agent directly after randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete